CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19-CAR-T 细胞中的表观遗传特征预测临床结局
英文原题：An epigenetic signature in CD19-CAR T cells predicts clinical outcome.
查看英文原题
An epigenetic signature in CD19-CAR T cells predicts clinical outcome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
表观遗传谱对过继性T细胞免疫疗法的潜在影响目前尚不清楚。在《美国国家癌症研究所杂志》最近的一项研究中，Garcia-Prieto等人表明，CD19-CAR-T 细胞的特定DNA甲基化谱与B细胞恶性肿瘤患者临床结局改善相关。
展开英文摘要原文
The potential impact of epigenetic profiles on adoptive T cell immunotherapies is currently unknown. In a recent study in the Journal of the National Cancer Institute, Garcia-Prieto et al. show that specific DNA methylation profiles of CD19-CAR T cells are associated with improved clinical outcome of patients with B cell malignancies.
论文信息
- 作者
- Simonetta F、Bertoni F
- 第一作者单位
- Division of Hematology, Department of Oncology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland; Translational Research Centre in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.Switzerland
- 通讯作者单位
- Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Electronic address: francesco.bertoni@ior.usi.ch.Switzerland
- 期刊
- Trends in cancer2022 Feb
- 原文标识
- PubMed 34972674 · DOI 10.1016/j.trecan.2021.12.005